Medicinal composition of calcium-containing antagonist, A II receptor antagonist and statins

A receptor antagonist, calcium ion antagonist technology, applied in the field of medicine, can solve the problem of unsatisfactory blood pressure effect and the like

Inactive Publication Date: 2010-04-07
王丽燕
View PDF5 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This pharmaceutical composition is a combination of amlodipine and statins, which has the effect of lowering blood pressure and l

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition of calcium-containing antagonist, A II receptor antagonist and statins
  • Medicinal composition of calcium-containing antagonist, A II receptor antagonist and statins
  • Medicinal composition of calcium-containing antagonist, A II receptor antagonist and statins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0162] Embodiment 1: levamlodipine besylate, telmisartan and atorvastatin calcium tablet

[0163]

[0164] Preparation:

[0165] (1) Granulation of atorvastatin calcium granules

[0166] Step 1. Pass various solid raw and auxiliary materials through No. 5 to No. 6 sieves, and set aside;

[0167] Step 2, dissolving polysorbate 80 in purified water at 45°C to 60°C, adding hydroxypropyl cellulose, and cooling the solution to room temperature;

[0168] Step 3, mixing atorvastatin calcium, calcium carbonate, microcrystalline cellulose, precrosslinked starch, crospovidone and croscarmellose sodium in a granulator;

[0169] Step 4. Mix the powder mixture from step 3 and the solution from step 2 in the granulator, and stir while adding to make a suitable soft material. If necessary, adjust its pH to 5.5-10.0. Use No. 2 Sieve to make wet granules;

[0170] Step 5, dry the granules in the drying equipment, sieve the granules with No. 2 sieve after drying, and finally make the moi...

Embodiment 2

[0176] Embodiment 2: amlodipine besylate, irbesartan and simvastatin capsules

[0177]

[0178]

[0179] Preparation:

[0180] (1) Granulation of Simvastatin Granules

[0181] Step 1. Pass various solid raw and auxiliary materials through No. 5 to No. 6 sieves, and set aside;

[0182] Step 2, dissolving polysorbate 80 in purified water at 50°C and adding hydroxypropyl cellulose, and cooling the solution to room temperature;

[0183] Step 3, mixing simvastatin, calcium carbonate, microcrystalline cellulose, precrossified starch, sodium lauryl sulfate and croscarmellose sodium in a granulator;

[0184] Step 4. Mix the powder mixture from step 3 and the solution from step 2 in the granulator, and stir while adding to make a suitable soft material, and adjust its pH value to 5.5-10.0 if necessary; use No. 2 Sieve to make wet granules;

[0185] Step 5, dry the granules in the drying equipment, sieve the granules with No. 2 sieve after drying, and finally make the moisture...

Embodiment 3

[0191] Embodiment 3: levamlodipine besylate, losartan potassium and atorvastatin calcium dispersible tablet

[0192]

[0193]

[0194] Preparation:

[0195] (1) Preparation of Atorvastatin Calcium Microcapsules

[0196] Step A, pass various solid raw and auxiliary materials through No. 5 to No. 6 sieves respectively, and set aside;

[0197] Step B. Dissolve gelatin and gum arabic in purified water respectively, stir to make them fully dissolved, add atorvastatin calcium and cross-linked carboxymethyl cellulose sodium to gum arabic, ultrasonic emulsify for 45 minutes, and gelatin solution and Mix the gum arabic solution into a three-necked flask, control the stirring speed at 200-400rpm, heat in a water bath, keep the temperature at 45°C-50°C, adjust the pH value of the system to 3.5-4.0, conduct the condensation reaction for 55 minutes, and lower the temperature of the system to 2 ℃-8℃, add formaldehyde with a mass concentration of 25% and a glutaraldehyde solution wit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicinal composition, which consists of the following parts: a calcium ion antagonist (CCB) or pharmaceutically acceptable salt thereof, an angiotensin II acceptor antagonist (ARB) or pharmaceutically acceptable salt or ester thereof, statins or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention also relates to a combined kit containing the active substances. The medicinal composition or the kit is used for treating hypertension, dyslipidemia, cerebrovascular disorder, stroke, coronary heart disease, diabetes, diabetic complication, angina, myocardial infarction, cardiac insufficiency, renal dysfunction, atherosclerosis, ventricular hypertrophy, aneurysm, myocardial ischemia, arrhythmia and glaucoma of patients, reducing the incidence rate and/or the death rate of cardiovascular and cerebrovascular disease, improving the adaptability of drug administration of the patients at the same time, and improving the life quality of the patients.

Description

technical field [0001] The present invention relates to a novel pharmaceutical composition, which is composed of the following parts: a certain amount of calcium ion antagonist or its pharmaceutically acceptable salt, a certain amount of angiotensin II receptor antagonist or its pharmaceutically acceptable salt. The invention relates to an acceptable salt or ester, a certain amount of statins or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier; it also relates to a combination kit containing the above-mentioned active substances, which belongs to the technical field of medicine. Background technique [0002] Due to the development of social economy and the change of people's lifestyle, the prevalence rate of hypertension in our country shows a continuous growth trend. According to the results of the national nutrition and health status survey in 2002, the prevalence rate of hypertension among adults in my country reached 18.8%. 160 million ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61P9/12A61P3/06A61P9/10A61P13/12A61P3/10A61P9/00A61P9/06A61P9/04A61P27/06
Inventor 王丽燕
Owner 王丽燕
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap